In a recent presentation featured at the Midwest Business Group on Health's Mental Health Forum, an expert shed light on the evolving landscape shaped by the Mental Health Parity and Addiction Treatment Act.
In a recent presentation featured at the Midwest Business Group on Health's Mental Health Forum, an expert shed light on the evolving landscape shaped by the Mental Health Parity and Addiction Treatment Act. Margaret Faso, executive director of the American Health Policy Institute and senior director of Public Policy, HR Policy Association, discussed the intricacies of this legislation underscoring the newfound challenges confronting employers and health care providers.
"The Mental Health Parity and Addiction Act has been out since 2008. This has been law and requirement on employer plans so while DOL [Department of Labor] has been, I would say, understanding of the fact that these are increased requirements on employers and recognizing the fact that employers have been trying to improve their mental health benefits for their employees, there's also a tone of well, this isn't new, and you all should have been doing this from the very beginning," Faso said.
Among the focal points were heightened standards for outcomes data collection, the amplified stringency of audits, and the persistent hurdles posed by provider shortages and geographical limitations.
One of the discussion's central themes revolved around the act's potential ramifications on both employers and employees. Addressing this, Faso deliberated on the pros and cons of financial implications under the new regulatory framework. The critical importance of meticulously evaluating plan benefits and delegating responsibilities to third-party administrators to ensure compliance emerged as a recurrent motif throughout the discourse.
Action Items for Employers
Faso outlined several actionable steps that employers can take to navigate the complexities of the Mental Health Parity and Addiction Treatment Act effectively:
Key Insights and Challenges
Rule Changes for Employer Plans: With the enactment of this act, employers are mandated to ensure that mental health benefits are on par with medical benefits. This requirement places responsibility on employers to re-evaluate and potentially adjust their benefit structures to comply with the new regulations.
Employee Retirement Income Security Act (ERISA) of 1974 Regulations: Compliance with ERISA regulations presents a notable challenge for employers, particularly concerning the certification of comparative analyses for each NQTL. This necessitates a thorough understanding of ERISA requirements and diligent documentation of compliance efforts.
Mental Health and Substance Use Disorder Benefits: Employers express concerns about the equalization of prior authorization requirements for mental health and medical benefits. This raises questions about the impact on plan administration and the potential need for additional resources to manage the process effectively.
Health Care Plan Design and Compliance: Employers may face heightened costs and scrutiny for plan designs, especially concerning mental health and substance use disorder benefits. Balancing compliance with cost-effectiveness poses a significant challenge, requiring careful consideration of benefit design and allocation of resources.
Health Care Network Adequacy: Employers must address concerns regarding network adequacy and compliance with regulatory requirements. Delegating the analysis of third-party administrator contracts and ensuring robust networks are crucial steps to mitigate the risk of audits and maintain compliance with the Mental Health Parity and Addiction Treatment Act.
Overall, Faso acknowledged the complexity of the new requirements being placed on employer plans by the Mental Health Parity rule changes, including conducting detailed comparative analyses of benefits and collecting/evaluating outcomes data to ensure equal access to mental health services.
Leveraging AI and Community Health Workers to Boost Trial Access
January 4th 2025In this second part of our interview with Kasey Bond, MPH, NYU Langone Health, we discuss the contributions of community health workers to increasing clinical trial access and how technology—artificial intelligence (AI), in particular—can help to facilitate the process.
Read More
Frameworks for Advancing Health Equity: Pharmacy Support for Non-Hodgkin Lymphoma
December 19th 2024Rachael Drake, pharmacy technician coordinator, University of Kansas Health System, explains how her team collaborates with insurance companies and providers to support treatment access for patients with non-Hodgkin lymphoma.
Listen
HS Treatment Goals: Better Quality of Life, Not Just Control
January 3rd 2025For part 3 of our discussion with Chris Sayed, MD, we tackle several important topics in the hidradenitis suppurative (HS) and inflammatory disease space: patient quality of life, medication and treatment goals, and the possibility of a cure.
Read More
BeiGene’s Mehrdad Mobasher, MD, MPH, Discusses CLL Data, Pipeline Following ASH 2024
January 2nd 2025This interview will appear in the January 2025 issue of Evidence-Based Oncology, our annual recap of the American Society of Hematology Meeting and Exposition. After this article went to press, the company announced its ticker symbol on the Nasdaq will change today.
Read More